Lead Product(s) : ABL301
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABL301 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : ABL301
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABL301
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,060.0 million
Deal Type : Collaboration
Details : ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $75.0 million
January 11, 2022
Lead Product(s) : ABL301
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,060.0 million
Deal Type : Collaboration